For the roughly 1.5 billion people living with soil-transmitted helminth infections worldwide, effective vaccines have remained elusive partly because traditional trial designs struggle to detect modest efficacy signals in complex endemic environments. Controlled human infection models offer a shortcut — deliberately exposing healthy volunteers to calibrated parasite doses in clinical settings — and a new review synthesizes what two decades of such work has revealed about hookworm and schistosomiasis vaccine development.
Both the controlled human schistosomiasis infection model (CHI-S) and the controlled human hookworm infection model (CHHI) have demonstrated acceptable safety profiles and reliable infection detection, qualifying them as credible platforms for early-phase immunization assessment. The two pathogens, though both helminths, behave strikingly differently in controlled settings. Schistosome exposure produces dose-dependent systemic symptoms, constraining challenge doses to levels below those seen naturally in endemic regions. Hookworm models, by contrast, allow infection intensities comparable to mild-to-moderate field burdens, and skin reactions rather than systemic effects dominate the adverse-event profile. Immunologically, short-term schistosome infection appears to promote immune tolerance — a finding with direct implications for vaccine antigen design — while hookworm provokes a distinct host response pattern.
These mechanistic contrasts matter enormously for vaccine strategy. Immune tolerance induced by schistosomes could undermine adjuvant choices and dosing schedules that work well against other pathogens. From a broader research landscape perspective, controlled human infection models have already transformed malaria and typhoid vaccine pipelines by compressing early efficacy testing from years to months — a precedent that makes their helminth application logically compelling but not yet proven to predict field outcomes. Key limitations remain: volunteer populations in these trials are typically immunologically naive Westerners, whose responses may diverge substantially from semi-immune individuals in endemic settings. Translational validity — whether model-derived efficacy signals replicate in Phase III field trials — is the discipline's central unanswered question. Nonetheless, this review marks an incremental but meaningful consolidation of evidence supporting controlled infection platforms as indispensable tools in neglected tropical disease vaccine development.